|Bid||313.00 x 800|
|Ask||366.24 x 1200|
|Day's Range||364.06 - 375.74|
|52 Week Range||312.33 - 449.38|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||49.45|
|Earnings Date||Oct. 28, 2021|
|Forward Dividend & Yield||1.36 (0.37%)|
|Ex-Dividend Date||Aug. 13, 2021|
|1y Target Est||470.44|
Study Evaluates Effectiveness of QuikClot Control+® Hemostatic Device in Patients Undergoing Cardiac SurgeryWAYNE, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the completion of patient enrollment in a clinical study evaluating the performance of the QuikClot Control+® Hemostatic Device for mild to moderate (Class I and II) bleeding in cardiac procedures as compared to standard gauze. The primary effi
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WAYNE, Pa., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, October 28, 2021. To register for the conference call and receive dial-in information, please use the following link: http://www.directeventreg.com/registration/event/4079822. The call can also be accessed through a live audio webcast on the company’s website teleflex.com.